Trends in Biotechnology
OpinionFrontiers in cancer nanomedicine: directing mass transport through biological barriers
Introduction
In a seminal paper, Hanahan and Weinberg [1] identified six fundamental acquired capabilities as the shared-trait identifiers of the very diverse family of heterogeneous diseases collectively termed ‘cancer’. These are: tissue invasion and metastasis; sustained angiogenesis; self-sufficiency in growth signals; limitless replicative potential; evasion of apoptosis; and insensitivity to anti-growth signals. Tissue invasion and metastasis are exquisitely cancer-defining transport phenomena at the cellular level (Box 1). All cancer hallmark mechanisms are based on a complex set of defects in the regulatory circuitry that governs normal cell homeostasis and proliferation. Regulatory circuitries at the cell level, in turn, are based on information flow pathways that involve mass transport at the molecular level, because their effectors are cascades of interaction among molecules endowed with a coordinated set of mutual recognition specificities. For instance, extra-cellular transport properties crucially impact cell proliferation through signals received by the cell via trans-membrane receptors that bind diffusible growth factor, cell adhesion molecules, and extra-cellular matrix components. The hallmark of acquired self-sufficiency in growth signals is known to be related to over-expression of growth factor receptors (e.g. EGF, HER2/neu) or receptor type switching (integrins), and might be impacted by disruptions in the signal transport chain, such as by independent or enhanced signaling resulting from receptor over-expression, or other causes. Dys-regulation of the downstream receiving and processing of signals emitted by ligand-activated growth factor receptors and integrins [1] is a transport-based type of mechanism for the induction of self-sufficiency in growth signals (e.g. SOS-Ras-Raf-MAPK pathway). The acquisition of insensitivity to antigrowth signals, which characterizes a large majority of cancers, comprises molecular processing components, which are interrelated to transport properties and the emergence of dys-regulated transport barriers to signaling molecules. Apoptosis controls are largely embedded in cell-to-cell contact signals that mandate the preservation of ‘health’ architectural configurations, and are therefore impacted by transport differentials in cells and molecules.
Collectively, these observations suggest a novel framework for the understanding of cancer, based on aberrations of mass transport at all levels, from molecules to the full organism. This paper is dedicated to identifying fundamental elements of this framework, and proposing novel, transport oncophysics-based diagnostic and therapeutic strategies. Nanotechnologies naturally emerge as the fundamental enabling platforms for this approach – that is, the novel frontier of cancer nanomedicine.
Section snippets
Cancer as a multi-scale mass-transport pathology
Cancer is a disease of the cell, which is inextricably linked to its surrounding biological milieu through a complexity of interactions with its microenvironment and distant sites within the host organism 1, 2. Both the proximal contact and the remote interactions centrally involve mass transport-based information transfer, in the form of molecular signals, the directed movement of cells, and the dynamic elaboration of tissue. The higher-scale portrait of cancer that emerges is that of a
Conclusions
Mass transport differentials are defining characteristics of cancer. Biological barriers are determinants of sufficient relevance in mass transport differentials that a new operational (“oncophysics”) classification of individual lesions might be envisioned based on the characteristics of transport through biobarriers. Nano- and micro-particulates are ideal probes for the study of mass transport differentials in cancer, and, as an immediate corollary, are perfectly suited to the preferential
Acknowledgments
Biana Godin, Paolo Decuzzi, Rita Serda and Tong Sun are gratefully acknowledged for their insightful discussion of the manuscript, and assistance in its preparation. Matt Landry is gratefully recognized for his artistry in the preparation of Figure 1. The author acknowledges financial support from the following sources: DODW81XWH-09-1-0212, DODW81XWH-07-2-0101; NASA NNJ06HE06A; NIH RO1CA128797, NIH – R33 CA122864, NIH U54CA143837 and State of Texas, Emerging Technology Fund.
References (103)
- et al.
The hallmarks of cancer
Cell
(2000) - et al.
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
Adv. Drug Deliv. Rev.
(2003) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
Adv. Enzyme Regul.
(2001)Exploiting the enhanced permeability and retention effect for tumor targeting
Drug Discov. Today
(2006)In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies
Neoplasia
(2007)The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows
J. Biomech.
(2008)Design of bio-mimetic particles with enhanced vascular interaction
J. Biomech.
(2009)- et al.
The adhesive strength of non-spherical particles mediated by specific interactions
Biomaterials
(2006) - et al.
The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles
Biomaterials
(2007) - et al.
The receptor-mediated endocytosis of nonspherical particles
Biophys J.
(2008)
Design maps for nanoparticles targeting the diseased microvasculature
Biomaterials
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature
Biomaterials
Critical determinants of metastasis
Semin Cancer Biol.
Integrin signaling and cell growth control
Curr. Opin. Cell Biol.
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation
Curr. Opin. Cell Biol.
Biological applications of dendrimers
Curr. Opin. Chem. Biol.
An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells
Nanomedicine
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates
Adv. Drug Deliv. Rev.
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Nat. Rev. Cancer
Transport of molecules, particles, and cells in solid tumors
Annu. Rev. Biomed. Eng.
Delivery of novel therapeutic agents in tumors: physiological barriers and strategies
J. Natl. Cancer Inst.
Antibiological barrier nanovector technology for cancer applications
Expert Opin. Drug Deliv.
Innovations in avoiding particle clearance from blood by Kupffer cells: 2010 cause for reflection
Crit. Rev. Ther. Drug Carrier Syst.
Signaling mechanisms regulating endothelial permeability
Physiol. Rev.
Interstitial hypertension in human breast and colorectal tumors
Cancer Res.
Oncotic pressure in solid tumors is elevated
Cancer Res.
Role of tumor–host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors
Proc. Natl. Acad. Sci. U. S. A.
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
Cancer Res.
Role of extracellular matrix assembly in interstitial transport in solid tumors
Cancer Res.
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation
Nat. Med.
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector
Cancer Res.
Matrix metalloproteinases-1 and -8 Improve the distribution and efficacy of an oncolytic virus
Cancer Res.
Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy
Clin. Cancer Res.
Recent approaches to intracellular delivery of drugs and DNA and organelle targeting
Annu. Rev. Biomed. Eng.
Chemical modification and formulation approaches to elevated drug transport across cell membranes
Expert Opin. Drug Deliv.
Fundamental concepts of the angiogenic process
Curr. Mol. Med.
Pharmacokinetic variability of anticancer agents
Nat. Rev. Cancer
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment
Proc. Natl. Acad. Sci. U. S. A.
Vascular permeability in a human tumour xenograft: molecular charge dependence
Br. J. Cancer
Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion
Ann. Biomed. Eng.
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)
Clin. Cancer Res.
Albumin-bound nanoparticle paclitaxel
Clin. Adv. Hematol. Oncol.
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo
Nat. Med.
Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma
Clin. Cancer Res.
Drug penetration in solid tumours
Nat. Rev. Cancer
Evaluation of magnetic resonance imaging-based prostate-specific antigen density of the prostate in the diagnosis of prostate cancer
Int. J. Urol.
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies
Clin. Cancer Res.
Nanotechnology - challenge and opportunity in clinical applications
Angew. Chem. Int. Ed. Engl.
A theoretical model for the margination of particles within blood vessels
Ann. Biomed. Eng.
Cited by (241)
Peptide-nanoparticle conjugates as a theranostic platform
2024, Coordination Chemistry ReviewsIn situ cellular hitchhiking of nanoparticles for drug delivery
2024, Advanced Drug Delivery ReviewsFluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies
2023, Medicine in Drug DiscoverySafety assessment of different unloaded polymeric nanocapsules in Caenorhabditis elegans
2023, Comparative Biochemistry and Physiology Part - C: Toxicology and PharmacologyStimuli-responsive polyprodrug for cancer therapy
2022, Materials Today AdvancesSimultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances
2022, European Journal of Pharmacology